NASDAQ:IMGN - ImmunoGen Stock Price, Forecast & News

ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."

ImmunoGen, Inc. (NASDAQ:IMGN) issued its quarterly earnings results on Friday, November, 1st. The biotechnology company reported ($0.15) EPS for the quarter, topping analysts' consensus estimates of ($0.19) by $0.04. The biotechnology company earned $13.30 million during the quarter, compared to analysts' expectations of $10.38 million. The business's quarterly revenue was up 22.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.32) EPS. View ImmunoGen's Earnings History.

ImmunoGen is scheduled to release their next quarterly earnings announcement on Friday, February 14th 2020. View Earnings Estimates for ImmunoGen.

9 analysts have issued 1 year price objectives for ImmunoGen's shares. Their forecasts range from $2.50 to $9.00. On average, they anticipate ImmunoGen's stock price to reach $4.28 in the next twelve months. This suggests that the stock has a possible downside of 18.8%. View Analyst Price Targets for ImmunoGen.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last year. There are currently 1 sell rating, 6 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ImmunoGen.

News articles about IMGN stock have been trending very negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. ImmunoGen earned a media sentiment score of -3.6 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for ImmunoGen.

ImmunoGen saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 12,550,000 shares, an increase of 14.2% from the December 15th total of 10,990,000 shares. Based on an average trading volume of 2,430,000 shares, the days-to-cover ratio is currently 5.2 days. Approximately 8.5% of the company's shares are short sold. View ImmunoGen's Current Options Chain.

Some companies that are related to ImmunoGen include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmunoGen investors own include Immunomedics (IMMU), Pfizer (PFE), Micron Technology (MU), Exelixis (EXEL), Nektar Therapeutics (NKTR), NVIDIA (NVDA), Seattle Genetics (SGEN), Alibaba Group (BABA), Gilead Sciences (GILD) and Synergy Pharmaceuticals (SGYP).

ImmunoGen's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Arden Trust Co (0.01%). Company insiders that own ImmunoGen stock include Anna Berkenblit, Daniel M Junius, David Brannon Johnston, Mark Alan Goldberg, Mark J Enyedy, Richard J Gregory and Thomas Ryll. View Institutional Ownership Trends for ImmunoGen.

IMGN stock was sold by a variety of institutional investors in the last quarter, including Arden Trust Co. Company insiders that have sold ImmunoGen company stock in the last year include Mark J Enyedy and Thomas Ryll. View Insider Buying and Selling for ImmunoGen.

Shares of IMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IMGN stock can currently be purchased for approximately $5.27.

ImmunoGen has a market capitalization of $788.92 million and generates $53.82 million in revenue each year. The biotechnology company earns $-168,840,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis. ImmunoGen employs 296 workers across the globe.View Additional Information About ImmunoGen.

The official website for ImmunoGen is http://www.immunogen.com/.

ImmunoGen's mailing address is 830 WINTER ST, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 781-895-0600 or via email at [email protected]